Patient Management for Medication Simplification During Care Transitions

Abstract

Medication simplification during care transitions remains an essential, yet challenging, aspect of patient management. Care transitions—such as hospital admission, discharge, or movement between care settings—are high-risk periods for medication errors, polypharmacy, and adverse drug events. This review provides an evidence-based appraisal of the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, recent advances, and guideline recommendations regarding medication simplification in transitional care. Emphasis is placed on the mechanisms underlying medication complexity, clinical implications of simplification, and practical strategies rooted in recent research and international guidelines. The article aims to enhance clinician awareness and inform best practices for optimizing pharmacotherapy during care transitions, ultimately improving patient outcomes and safety.

Introduction

Transitions of care are critical junctures in the patient journey, characterized by complex handoffs and vulnerability to adverse medication-related outcomes. Medication simplification—the process of rationalizing and streamlining medication regimens—seeks to reduce polypharmacy, enhance adherence, and minimize error risk. With the global population aging and chronic multimorbidity increasing, the importance of effective medication management during transitions has never been greater. Clinicians face the dual challenge of maintaining therapeutic efficacy while reducing regimen complexity, and must navigate evolving guidelines, drug formularies, and patient-specific considerations. Understanding the science and art of medication simplification is central to providing safe, high-quality transitional care.

Epidemiology / Disease Burden

Polypharmacy is prevalent in populations most likely to experience care transitions, such as the elderly and those with multiple chronic conditions. Studies indicate that up to 60% of older adults are prescribed five or more medications upon hospital admission, with nearly 40% experiencing changes to their regimen during hospitalization. Medication discrepancies occur in up to 70% of patients at discharge, and adverse drug events contribute to 20% of hospital readmissions within 30 days. The burden is amplified in long-term care, rehabilitation, and home care settings, where fragmented communication exacerbates the risk. The cost implications are significant, with preventable medication-related hospitalizations estimated to exceed billions in annual healthcare expenditures globally.

Pathophysiology

The pathophysiology of medication complexity during transitions is multifaceted, involving pharmacokinetic and pharmacodynamic changes, drug-drug interactions, and altered organ function. Aging and disease progression impact hepatic and renal clearance, increasing the risk of accumulation and toxicity. Polypharmacy compounds these effects, heightening the probability of adverse reactions. Transitions often entail abrupt therapy changes, incomplete communication, and discrepancies between prescribers' intentions and patients' understanding, further complicating safe medication use. The interplay between regimen complexity and cognitive, functional, and adherence barriers underpins the need for simplification.

Risk Factors

Risk factors for medication-related harm during transitions include advanced age, frailty, cognitive impairment, limited health literacy, polypharmacy, and multimorbidity. Frequent transitions—such as repeated hospital admissions or moves between care facilities—amplify exposure to potential errors. Additional contributors include inadequate medication reconciliation, incomplete documentation, lack of standardized protocols, and insufficient patient or caregiver education. Socioeconomic disparities and fragmented healthcare systems further elevate risk, particularly among vulnerable populations.

Clinical Features

Clinically, medication-related issues manifest as adverse drug events, nonadherence, therapeutic failure, or drug toxicity. Symptoms may be nonspecific, such as delirium, falls, gastrointestinal disturbances, or altered mental status—often attributed to underlying illnesses rather than medications. Polypharmacy increases the likelihood of drug-drug and drug-disease interactions, complicating clinical assessment. Unrecognized medication discrepancies can lead to duplication, omission, or inappropriate continuation/discontinuation of therapies, undermining patient safety and outcomes.

Diagnosis

Diagnosis of medication-related problems during transitions hinges on comprehensive medication reconciliation—a systematic process comparing pre- and post-transition medication lists. Identification of discrepancies, such as omissions, duplications, dosing errors, or unintended changes, is imperative. Clinical evaluation should incorporate review of recent laboratory results, assessment of renal and hepatic function, and close monitoring for signs of adverse drug reactions. Collaboration with pharmacists, use of standardized medication review tools (e.g., Beers Criteria, STOPP/START), and patient or caregiver interviews are critical to accurate medication assessment.

Treatment & Management

Medication simplification strategies center on minimizing unnecessary medications, optimizing dosing regimens, and aligning therapy with the patient’s goals and clinical status. Interventions include deprescribing—systematic withdrawal of medications with limited benefit or high risk—consolidating dosing schedules, and switching to fixed-dose combinations or long-acting formulations where appropriate. Multidisciplinary collaboration is essential, involving physicians, pharmacists, nurses, and case managers. Patient and caregiver engagement, clear communication, and robust documentation are vital to ensure safe transitions. Tailoring regimens to cognitive and functional abilities, providing education, and leveraging medication adherence aids can further enhance outcomes.

Recent Advances / Emerging Therapies

Recent advances include the development of electronic medication reconciliation platforms, clinical decision support systems, and artificial intelligence tools to flag high-risk regimens and detect potential interactions. Emerging evidence supports pharmacist-led medication review and deprescribing interventions, which have demonstrated reductions in polypharmacy, hospital readmissions, and adverse drug events. Studies highlight the utility of shared decision-making models and patient-centered care plans in facilitating successful medication simplification. Ongoing research explores the role of digital health, remote monitoring, and telepharmacy in supporting medication management during transitions.

Guideline Recommendations

International guidelines, including those from the World Health Organization, Institute for Healthcare Improvement, and national societies, emphasize the importance of structured medication reconciliation at every transition point. Recommendations advocate for regular medication review, deprescribing where appropriate, and individualized care planning. The use of explicit criteria (Beers, STOPP/START), patient and caregiver education, and multidisciplinary teamwork are underscored as best practices. Guidelines increasingly recognize the need for system-level interventions—such as integrated electronic health records and standardized handoff procedures—to support safe and effective medication management.

Conclusion

Medication simplification during care transitions is a cornerstone of safe, effective, and patient-centered healthcare. Clinicians must be vigilant in identifying and addressing medication complexity, employing evidence-based strategies to optimize regimens and mitigate risk. Recent technological advances and evolving guidelines offer new opportunities to enhance transitional care, but success ultimately depends on interdisciplinary collaboration and patient engagement. Ongoing research and quality improvement initiatives will be pivotal in refining best practices and ensuring that medication management during transitions supports optimal health outcomes for all patients.